This finding was further supported by an analysis of 13,857 prostate cancer cases from 29 studies registered in cBioPortal, where the frequency of each specific TP53 mutation was similarly below 1% (https://www.cbioportal.org/). This evidence concerns the gene TP53 and prostate carcinoma.